linjc16/ctgov huggingface dataset:
Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients

Study Overview
=================
Brief Summary
-----------------
Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of Multiple Sclerosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Multiple Sclerosis patients.

Official Title
-----------------
Extensive Clinical Trial Experiences of Multiple Sclerosis Patients To Determine Trial Attributes Affecting Completion Rates For Specific Demographic Groups

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant has a diagnosis of Multiple Sclerosis Patient has self-identified as planning to enroll in an interventional clinical trial for Multiple Sclerosis Patient is at least 18 years of age Exclusion Criteria: Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form No diagnosis of Multiple Sclerosis confirmed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a Multiple Sclerosis Clinical Trial |  | 3 months | 
| Number of patients who remain in Multiple Sclerosis clinical trial until completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Sclerosis, Sclerosis
Plasma Brain Natriuretic Peptide Levels in Pregnancy

Study Overview
=================
Brief Summary
-----------------
To evaluate the maternal blood concentrations of brain natriuretic peptide (BNP) during the second and third trimesters of a normal pregnancy. We will attempt to define a normal range for pregnancy and any outliers that may serve as markers for abnormal cardiovascular physiology.

Detailed Description
-----------------
The brain natriuretic peptide (BNP) is a useful marker for volume overload, increased filling pressures and stretching of the myocardium. The current literature contains limited and unreliable information regarding normal BNP values in pregnancy. After baseline echocardiogram to detect individuals with asymptomatic structural defects, the participants will submit to 3 blood draws during the second and third trimester and at delivery to determine normal pregnancy values.

Official Title
-----------------
Plasma Brain Natriuretic Peptide Levels in Pregnancy

Conditions
-----------------
Cardiomyopathy, Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women age 18 to 40 second trimester of pregnancy Exclusion Criteria: known cardiac or valvular disease, atrial fibrillation or other arrhythmia, pulmonary hypertension, chronic hypertension, hypertensive disorders of pregnancy, morbid obesity (BMI > 40 kg/meter squared) history of sleep apnea multiple gestation known renal dysfunction medications known to affect cardiac function current or past abnormal echocardiogram

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Healthy pregnant women, 18-40 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
brain natriuretic peptide, pregnancy, biomarker
Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis

Study Overview
=================
Brief Summary
-----------------
To evaluate the discriminative power of BIS monitoring to classify the degree of mental state associated with the PCT graded sepsis cascade, and to assess its utility for monitoring the improvement or deterioration of sepsis.

Detailed Description
-----------------
To evaluate the discriminative power of BIS monitoring to classify the degree of mental state associated with the PCT graded sepsis cascade, and to assess its utility for monitoring the improvement or deterioration of sepsis. The primary endpoint of our study was to use an artefact-free 10-min mean BIS value to classify the degree of sepsis. As secondary endpoints, we correlated the mean BIS value to various mental state and sepsis parameters; PCT, C-reactive protein (CRP), Glasgow coma scale, and sequential organ failure assessment (SOFA) score. In a longitudinal study, patients' PCT sepsis grades were reassessed at a later time point and a second artefact-free 10-min mean BIS value was recorded to evaluate BIS evolution within the same patient.

Official Title
-----------------
Sensitivity and Specificity of Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis, Severe Sepsis and Septic Shock and Multiple Organ Failure (MOF)

Conditions
-----------------
Sepsis, Severe

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with sepsis patients with sepsis Exclusion Criteria: Patients who received drugs that would interfere with BIS monitoring
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bispectral Index (BIS)-Electroencephalography (EEG) derived parameter correlated to the severity of Sepsis as indicated by Procalcitonin (PCT) biomarker. | Bispectral Index (BIS)-Electroencephalography (EEG) derived parameter (scale from 0=brain dead to 100= normal EEG) will be monitored and correlated to the severity of Sepsis as indicated by daily measured Procalcitonin (PCT) biomarker (<0.5 micg/L =no sepsis up to 100 micg/L =Septic shock) | Time point 1= On CCU admission, Time point 2= day 3 of CCU admission, Time point 3= on release from CCU. |
An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Study Overview
=================
Brief Summary
-----------------
This is a phase 2, multicenter, single arm, open-lable study of ICP-192. The purpose of this study is to evaluate efficacy of ICP-192 in subjects with surgically unresectable or metastatic bladder urothelial cancer.

Detailed Description
-----------------
bladder urothelial cancer

Official Title
-----------------
A Phase 2, Multicenter, Single Arm, Open-lable Study of ICP-192 in Subjects With Surgically Unresectable or Metastatic Bladder Urothelial Cancer With FGFR Genetic Aberrations.

Conditions
-----------------
Bladder Urothelial Cancer

Intervention / Treatment
-----------------
* Drug: ICP-192


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria： Signed the ICF and Age ≥ 18 years old, either sex. ECOG ≤ 1. Life expectancy of at least 3 months. Histologically confirmed unresectable or metastatic bladder urothelial cancinoma. At least one measurable lesion as the target lesion at screening assessed according to RECIST V1.1 Exclusion Criteria: Prior treatment with selective FGFR inhibitors or FGFR antibodies. Any corneal or retinal abnormalities that may result in an increased risk of ocular toxicity.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ICP-192<br>ICP-192 | Drug: ICP-192<br>* ICP-192 is a white, round, uncoated table<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ORR | Objective Response Rate | From the time of first dose until objective disease progression, an average of 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DOR | Duration of response | From the time of first dose until objective disease progression, an average of 6 months | 
| DCR | Disease Control Rate | From the time of first dose until objective disease progression, an average of 6 months | 
| PFS | Progression Free Survival | From the time of first dose until objective disease progression, an average of 6 months | 
| OS | Overall survival | From the time of first dose until objective disease progression, an average of 1 months |
Pulsed Radiofrequency of S2-4 Versus Ganglion Impar Neurolysis for Severe Perianal and Perineal Pain in Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Perineal pain resulting from malignancy is usually severe. Pain can be related to the malignancy or as a complication related to the treatment. several modalities are adopted to control such pain starting from medical management to interventional pain procedures.

Detailed Description
-----------------
Perineal pain resulting from malignancy is usually severe. Pain can be related to the malignancy or as a complication related to the treatment. several modalities are adopted to control such pain starting from medical management to interventional pain procedures. Ganglion impar block has been traditionally used for treatment of such perineal pain. Radiofrequency of sacral dorsal root ganglia can be used as an alternative for pain control.

Official Title
-----------------
Bilateral Pulsed Radiofrequency of Dorsal Root Ganglia of S2-4 Versus Ganglion Impar Neurolysis for Severe Perianal and Perineal Pain in Cancer Patients

Conditions
-----------------
Analgesia

Intervention / Treatment
-----------------
* Procedure: Ganglion Impar Neurolysis
* Procedure: Bilateral S2, S3 and S4 Pulsed radiofrequency


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged 18-75 years ASA II-III with perianal and perineal pain related to cancer Exclusion Criteria: patient refusal coagulation defects abnormal kidney or liver functions local infection at site of injection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ganglion Impar Neurolysis<br>Block of ganglion impar using neurolytic | Procedure: Ganglion Impar Neurolysis<br>* block of Ganglion Impar by neurolytic drug<br>|
| Experimental: Bilateral S2, S3 and S4 Pulsed radiofrequency<br>Pulsed radiofrequency of S2-S4 | Procedure: Bilateral S2, S3 and S4 Pulsed radiofrequency<br>* Bilateral S2, S3 and S4 Pulsed radiofrequency<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analogue scale | the score of visual analogue scale score, with minimum score of 0 and maximum of 10, with higher scores meaning more severe pain | Two hours |
Laparoscopic Prostatectomy for Chronic Prostatitis

Study Overview
=================
Brief Summary
-----------------
Prostatitis is an inflammation of the prostate, an pelvic organ of men. Prostatitis can cause great discomfort which varies but can include pelvic pain, pelvic pressure, a vague sense of discomfort, a feeling of malaise and fatigue, fever, burning on urination, pain on reaching orgasm, and bleeding. In many men the symptoms of prostatitis can be chronic. It is estimated that in the United States chronic prostatitis is responsible for as many as two million doctor visits a year. The disease can be ruinous, interfering with work, intimacy, and other things. The causes of chronic prostatitis are not understood. The treatments commonly used, including antibiotics and prostate massage, work poorly. We now have evidence that laparoscopic prostatectomy can eliminate the misery of chronic prostatitis. This trial aims to quantify and better characterize the effect of laparoscopic prostatectomy on the symptoms of chronic prostatitis.

Official Title
-----------------
Laparoscopic Prostatectomy for Chronic Prostatitis

Conditions
-----------------
Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Intervention / Treatment
-----------------
* Procedure: laparoscopic prostatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 30 and greater NIH-CPSI score of 25 and higher Symptom duration of at least one year Failed treatment with antibiotics and/or other medications Exclusion Criteria: Inability to tolerate Anesthesia Inability to speak any English

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: one<br>laparoscopic prostatectomy | Procedure: laparoscopic prostatectomy<br>* laparoscopic prostatectomy<br>* Other names: minimally invasive prostate surgery;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NHI CPSI (chronic prostatitis symptom index) |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic, prostatitis, prostate, pain, pelvic, pelvis, inflamation
Formative Phase of Reducing Hazardous Alcohol Use & HIV Viral Load

Study Overview
=================
Brief Summary
-----------------
This study is the Formative Phase of a larger study; once this phase is completed, enrollment into the randomized controlled trial (RCT Phase) will begin. The primary objective of the Formative Phase is to gain a better understanding of the context in which drinking alcohol among ART client in Vietnam occurs, in order to culturally tailor the intervention to be tested in the RCT Phase. Formative Phase activities will consist of up to 40 in-depth interviews with hazardous drinkers who are either: a) ART clients in one of the ART clinics in Thai Nguyen, or b) who are people who inject drugs (PWID) that are not recruited from the ART clinics (whom we will refer to as general population PWID).

Official Title
-----------------
Formative Phase of Reducing Hazardous Alcohol Use & HIV Viral Load: An RCT in ART Clinics in Vietnam

Conditions
-----------------
Alcohol Drinking, Alcohol Use Norms, Alcohol Use Among ART Clients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: being 18-49 years of age; having an AUDIT score ≥ 8 (hazardous alcohol use); being a current ART client at one of the Thai Nguyen ART clinics or a general population PWID; being capable of providing voluntary informed consent. Exclusion Criteria: being unable to participate in study activities due to psychological disturbance, cognitive impairment or threatening behavior; currently participating in other HIV, drug use or alcohol studies.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of heavy drinking episodes | This will be an assessment of how and why individuals engage in heavy drinking. As part of this exploration, we will assess: number of standard drinks consumed on those days that an individual drank number of days on which alcohol was consumed beyond recommended levels | during interviews |
Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Study Overview
=================
Brief Summary
-----------------
To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

Official Title
-----------------
Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Dinitrochlorobenzene


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have the following: Stage III or IV HIV infection. Provide informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Kaposi's sarcoma lesions in the proposed treatment sites. Liable to require radiation or chemotherapy during the course of the study. Not likely to survive the length of the study. Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.: holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine. Concurrent Medication: Excluded: Other Immunomodulators. Concurrent Treatment: Excluded: Radiation. Patients with the following are excluded: Kaposi's sarcoma lesions in the proposed treatment sites. Liable to require radiation or chemotherapy during the course of the study. Not likely to survive the length of the study. Obvious ultra-violet-irradiated skin damage in the treatment areas. Allergy to lidocaine. Prior Medication: Excluded: Prior DNCB therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dinitrochlorobenzene|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Langerhans Cells, Dinitrochlorobenzene, Acquired Immunodeficiency Syndrome, AIDS-Related Complex
Genetic Polymorphism and Israeli Top-level Athletes

Study Overview
=================
Brief Summary
-----------------
It is still unknown whether different genetic elements play a role in athletes' ability to create their area of specificity.In a study conducted in our laboratory few years ago, we genotyped 22 genes in 2 athletic groups (endurance and sprinters) and in age and gender matched nonathletic controls. Few of these genes were found to be associated with athletic performance and area of specificity. Since then a few more genes have been found that are related to athletic performance, and our aim in the current study is to expand our research to these new genes which include 3 genetic cascades: genes associated with body fluid balance and homeostasis, genes associated with muscle strength, and genes associated with bioenergy.

Conditions
-----------------
Top-level Athletes

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Top-level athletes Other athletes Exclusion Criteria: All others

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Top-level athletes<br> | Other: Blood sample<br>* Extraction of blood sample from top-level athletes<br>|
| Control group<br> | Other: Blood sample<br>* Extraction of blood sample from top-level athletes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genes related to top-level athletes |  | Four months |